NON-HODGKIN LYMPHOMA

This study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can reduce the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers who are…

This study tests whether specially trained immune cells from healthy donors can safely fight cancers and diseases caused by the Epstein-Barr virus (EBV). The cells are made quickly in the lab and stored in a bank, so they are ready for patients whose cancer has returned or not re…

This study tests a drug called acalabrutinib, alone or with other medicines, in 113 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to see if the drug is safe and shrinks tumors. This is an early-phase trial, so it focus…

This study tests whether adding special 'veto' cells to a stem cell transplant can help donor cells grow in the body without causing severe graft-versus-host disease (GVHD). It includes 16 people aged 12-75 with various blood cancers or bone marrow failure. The veto cells are tre…

This study tests a vaccine called Triplex to see if it can prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be dangerous for people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA…

This early-phase study tests whether adding the drug duvelisib after CAR T-cell therapy can help the immune cells survive longer and fight non-Hodgkin lymphoma or acute lymphocytic leukemia more effectively. About 42 adults who are eligible for approved CAR T-cell treatments will…

This early-phase study tests an oral drug called APG-2575 in adults with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to find a safe dose and check for side effects. About 74 participants will take the drug by mouth…

This early-phase study tests whether giving healthy donor natural killer (NK) cells along with two drugs (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach/esophageal, or blood cancers. The NK cells are meant to attack cance…

This study tests whether adding the drug vorinostat to standard care can lower the chance of graft-versus-host disease (GVHD) in children, teens, and young adults getting a bone marrow or blood stem cell transplant for blood cancers. About 43 participants will receive vorinostat …

This study tests an experimental drug called WTX-330 in about 100 adults with advanced solid tumors or non-Hodgkin lymphoma that hasn't responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. Researchers will also monitor si…

This early-phase study tests a new type of immune cell therapy (huCART19-IL18) for people with certain blood cancers that have come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to better find and attack cancer cells. The main goa…

This study tests a new drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma (a blood cancer). The goal is to see if the drug can shrink tumors and keep the cancer from growing for as long as possible. About 320 adults wi…

This early-stage study tests a new type of CAR-T cell therapy, made in record time, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose. About 21 adults will take part, and research…

This phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than standard chemotherapy for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to previous therapy. About 208 adults wit…

This study aimed to test a combination of two drugs, golcadomide and nivolumab, in adults with non-Hodgkin lymphoma that did not respond or returned after CAR-T cell therapy. The goal was to find the safest dose and see if the combination could shrink tumors. However, the study w…

This early-stage study tests a new treatment called SC291 for people with certain types of blood cancers (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or not responded to other treatments. SC291 is a type of immune cell therapy designed to find and at…

This early-phase study tests an experimental drug called GNC-038 in people with certain lymphomas (NK/T-cell lymphoma, AITL, and other non-Hodgkin lymphomas) that have returned or not responded to standard therapy. The main goals are to check the drug's safety, find the best dose…

This early-phase study tests whether a patient's own immune cells (T cells) can be genetically modified to recognize and attack non-Hodgkin lymphoma that has not responded to other treatments. About 31 adults with CD19-positive lymphoma will receive these 'CAR T cells' to see if …

This study tests whether adding low-dose radiation to the immunotherapy drug pembrolizumab can help people with relapsed or refractory non-Hodgkin lymphoma. Six adults with at least two measurable tumor sites are receiving the combination. The goal is to see how many patients ach…

This early-stage trial tests a new drug called GNC-038, a quad-specific antibody designed to attack cancer cells in people with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia. The main goals are to check the drug's safety, find the right dose, and see…

This study tests an experimental drug called DS-3201b in about 100 adults with non-Hodgkin lymphoma whose cancer has come back or stopped responding to standard treatments. The main goals are to find a safe dose and see how well the drug works. The study also checks how the drug …

This early-phase study tests whether giving targeted radiation before standard CAR T-cell therapy is safe and practical for people with relapsed or refractory B-cell lymphoma. About 20 participants will receive radiation to all active disease sites before their CAR T infusion. Th…

This study offers ongoing CC-122 treatment to 12 people with Non-Hodgkin Lymphoma who have already been taking it for over 5 years in earlier trials and are still seeing benefits. The main goal is to monitor safety and side effects over the long term. It is not a cure, but aims t…

This study looks at whether a special PET scan using a natural amino acid called methionine can help doctors see tumors in children and young adults with cancer. About 500 participants will get the scan to check if it can find tumors at diagnosis and tell the difference between a…

This early-phase trial tests whether giving a CMV vaccine to stem cell donors can boost the recipient's immunity after transplant. About 34 blood cancer patients receiving donor stem cells are involved. The goal is to prevent CMV viremia, a common and serious viral infection, wit…

This study looks at whether adding acupuncture to standard pain care can reduce the need for strong opioid painkillers in people with multiple myeloma, Hodgkin disease, or non-Hodgkin lymphoma who are getting high-dose chemotherapy. About 299 adults will be randomly assigned to r…

This study tests whether giving radiation over a shorter time (instead of the usual 5-6 weeks) is safe for people with lymphoma that has returned or not responded to treatment. About 30 participants will receive different shortened radiation doses to find the safest one. The goal…

This study looks at how blood cancers and stem cell transplants affect muscle function in 144 patients. Researchers want to see if muscle health can help predict complications like infections, relapse, or survival. The goal is to better understand the role of muscle strength at k…

This study follows 500 adults aged 18-65 who finished chemotherapy for certain cancers and are in remission. Over 5 years, researchers will check for 19 possible late side effects like heart problems, memory issues, and fatigue. The goal is to catch these problems early and impro…

This study tracks 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to watch for long-term side effects and safety issues over 15 years. No new treatment is given—just regular check-ups to see how patients are doing.…

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…